A review of CETP and its relation to atherosclerosis

Journal of Lipid Research

Volumn 45, Issue 11, 2004, Pages 1967-1974

  De Grooth, Greetje J ^a   Klerkx, Anke H E M ^a   Stroes, Erik S G ^a   Stalenhoef, Anton F H ^b   Kastelein, John J P ^a   Kuivenhoven, Jan Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesteryl ester transfer protein; Coronary artery disease; Dyslipidemia

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN B; ATORVASTATIN; CGS 25159; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PLACEBO; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VACCINE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ASIAN; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DYSLIPIDEMIA; GENE LINKAGE DISEQUILIBRIUM; HAMSTER; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPOPROTEIN METABOLISM; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; VOLUNTEER; ANIMAL; ARTERIOSCLEROSIS; BLOOD; GENETIC POLYMORPHISM; GENETICS; HYPERLIPIDEMIA; METABOLISM; MOUSE; RAT; RISK;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; HUMANS; HYPERLIPIDEMIAS; MICE; POLYMORPHISM, GENETIC; RATS; RISK;

EID: 17844373610     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.R400007-JLR200     Document Type: Review

References (97)

1. McGovern, P. G., J. S. Pankow, E. Shahar, K. M. Doliszny, A. R. Folsom, H. Blackburn, R. V. Luepker, and The Minnesota Heart Survey Investigators. 1996. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. N. Engl. J. Med. 334: 884-890.
2. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
3. Downs, J. R., M. Clearfield, S. Weis, E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, and A. M. Gotto, Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 279: 1615-1622.
4. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, B. R. Davis, and E. Braunwald. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335: 1001-1009.
5. Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, C. J. Packard. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333: 1301-1307.
6. Gotto, A. M., Jr. 2001. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 103: 2213-2218.
7. Despres, J. P., I. Lemieux, G. R. Dagenais, B. Cantin, and B. Lamarche. 2000. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 153: 263-272.
8. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am. J. Med. 62: 707-714.
9. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt, J. Wittes. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N. Engl. J. Med. 341: 410-418.
10. Manninen, V., M. O. Elo, M. H. Frick, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, and P. Koskinen. 1988. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J. Am. Med. Assoc. 260: 641-651.
11. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
12. Naqvi, T. Z., P. K. Shah, P. A. Ivey, M. D. Molloy, A. M. Thomas, S. Panicker, A. Ahmed, B. Cercek, and S. Kaul. 1999. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol. 84: 1011-1017.
13. Nofer, J. R., B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. von Eckardstein. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161: 1-16.
14. Ashby, D. T., K. A. Rye, M. A. Clay, M. A. Vadas, J. R. Gamble, and P. J. Barter. 1998. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18: 1450-1455.
15. Xia, P., M. A. Vadas, K. A. Rye, P. J. Barter, and J. R. Gamble. 1999. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274: 33143-33147.
16. Bisoendial, R. J., G. K. Hovingh, J. H. Levels, P. G. Lerch, I. Andresen, M. R. Hayden, J. J. Kastelein, and E. S. Stroes. 2003. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 107: 2944-2948.
17. Stein, O., and Y. Stein. 1999. Atheroprotective mechanisms of HDL. Atherosclerosis. 144: 285-301.
18. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13-27.
19. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105: 2159-2165.
20. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207.
21. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, M. E. Perlman, and M. J. Bamberger. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 1-9.
22. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Eng. J. Med. 350: 1505-1515.
23. Barter, P. J. 2002. Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. 3: 39-47.
24. Koizumi, J., H. Mabuchi, A. Yoshimura, I. Michishita, M. Takeda, H. Itoh, Y. Sakai, T. Sakai, K. Ueda, and R. Takeda. 1985. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 58: 175-186.
25. Yamashita, S., Y. Matsuzawa, M. Okazaki, H. Kako, T. Yasugi, H. Akioka, K. Hirano, and S. Tarui. 1988. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis. 70: 7-12.
26. Kurasawa, T., S. Yokoyama, Y. Miyake, T. Yamamura, and A. Yamamoto. 1985. Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. J. Biochem. (Tokyo). 98: 1499-1508.
27. Matsuzawa, Y., S. Yamashita, K. Kameda, M. Kubo, S. Tarui, and I. Hara. 1984. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity: a case report. Atherosclerosis. 53: 207-212.
28. Inazu, A., M. L. Brown, C. B. Hesler, L. B. Agellon, J. Koizumi, K. Takata, Y. Maruhama, H. Mabuchi, and A. R. Tall. 1990. Increased high-density lipoprotein levels caused by a common cholesterylester transfer protein gene mutation. N. Engl. J. Med. 323: 1234-1238.
29. Ikewaki, K., D. J. Rader, T. Sakamoto, M. Nishiwaki, N. Wakimoto, J. R. Schaefer, T. Ishikawa, T. Fairwell, L. A. Zech, and H. Nakamura. 1993. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92: 1650-1658.
30. Sakai, N., S. Yamashita, K. Hirano, M. Ishigami, T. Arai, K. Kobayashi, T. Funahashi, and Y. Matsuzawa. 1995. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur. J. Clin. Invest. 25: 332-339.
31. Ikewaki, K., M. Nishiwaki, T. Sakamoto, T. Ishikawa, T. Fairwell, L. A. Zech, M. Nagano, H. Nakamura, H. B. Brewer, Jr., and D. J. Rader. 1995. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96: 1573-1581.
32. Hirano, K., S. Yamashita, N. Nakajima, T. Arai, T. Maruyama, Y. Yoshida, M. Ishigami, N. Sakai, K. Kameda-Takemura, and Y. Matsuzawa. 1997. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan; marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17: 1053-1059.
33. Zhong, S., D. S. Sharp, J. S. Grove, C. Bruce, K. Yano, J. D. Curb, and A. R. Tall. 1996. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97: 2917-2923.
34. Hirano, K., S. Yamashita, N. Sakai, T. Arai, Y. Yoshida, S. Nozaki, K. Kameda-Takemura, and Y. Matsuzawa. 1995. Molecular defect and atherogenicity in cholesteryl ester transfer protein deficiency. Ann. N. Y. Acad. Sci. 748: 599-602.
35. Hirano, K., S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T. Arai, K. Yanagi, S. Takami, and M. Menju. 1995. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15: 1849-1856.
36. Barter, P. J., H. B. Brewer, Jr., M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall. 2003. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 160-167.
37. Moriyama, Y., T. Okamura, A. Inazu, M. Doi, H. Iso, Y. Mouri, Y. Ishikawa, H. Suzuki, M. Iida, J. Koizumi, H. Mabuchi, and Y. Komachi. 1998. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27: 659-667.
38. Bernard, S., P. Moulin, L. Lagrost, S. Picard, M. Elchebly, G. Ponsin, F. Chapuis, and F. Berthezene. 1998. Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J. Lipid Res. 39: 59-65.
39. Brousseau, M. E., J. J. O'Connor, Jr., J. M. Ordovas, D. Collins, J. D. Otvos, T. Massov, J. R. McNamara, H. B. Rubins, S. J. Robins, and E. J. Schaefer. 2002. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler. Thromb. Vasc. Biol. 22: 1148-1154.
40. Freeman, D. J., B. A. Griffin, A. P. Holmes, G. M. Lindsay, D. Gaffney, C. J. Packard, and J. Shepherd. 1994. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors: associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler. Thromb. 14: 336-344.
41. Kuivenhoven, J. A., P. de Knijff, J. M. Boer, H. A. Smalheer, G. J. Botma, J. C. Seidell, J. J. Kastelein, and P. H. Pritchard. 1997. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 17: 560-568.
42. Liu, S., C. Schmitz, M. J. Stampfer, F. Sacks, C. H. Hennekens, K. Lindpaintner, and P. M. Ridker. 2002. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis. 161: 469-474.
43. Ordovas, J. M., L. A. Cupples, D. Corella, J. D. Otvos, D. Osgood, A. Martinez, C. Lahoz, O. Coltell, P. W. Wilson, and E. J. Schaefer. 2000. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler. Thromb. Vasc. Biol. 20: 1323-1329.
44. van Venrooij, F. V., R. P. Stolk, J. D. Banga, T. P. Sijmonsma, A. van Tol, D. W. Erkelens, and G. M. Dallinga-Thie. 2003. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 26: 1216-1223.
45. Kuivenhoven, J. A., J. W. Jukema, A. H. Zwinderman, P. de Knijff, R. McPherson, A. V. Bruschke, K. I. Lie, and J. J. Kastelein. 1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338: 86-93.
46. Dachet, C., O. Poirier, F. Cambien, J. Chapman, and M. Rouis. 2000. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler. Thromb. Vasc. Biol. 20: 507-515.
47. Boekholdt, S. M., and J. F. Thompson. 2003. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J. Lipid Res. 44: 1080-1093.
48. Klerkx, A. H., M. W. Tanck, J. J. Kastelein, H. O. Molhuizen, J. W. Jukema, A. H. Zwinderman, and J. A. Kuivenhoven. 2003. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum. Mol. Genet. 12: 111-123.
49. Corbex, M., O. Poirier, F. Fumeron, D. Betoulle, A. Evans, J. B. Ruidavets, D. Arveiler, G. Luc, L. Tiret, and F. Cambien. 2000. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet. Epidemiol. 19: 64-80.
50. Corella, D., C. Saiz, M. Guillen, O. Portoles, F. Mulet, J. I. Gonzalez, and J. M. Ordovas. 2000. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis. 152: 367-376.
51. Klerkx, A. H. E. M., G. J. de Grooth, A. H. Zwinderman, J. W. Jukema, J. A. Kuivenhoven, and J. J. P. Kastelein. 2004. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur. J. Clin. Invest. 34: 21-28.
52. Goto, A., K. Sasai, S. Suzuki, T. Fukutomi, S. Ito, T. Matsushita, M. Okamoto, T. Suzuki, M. Itoh, K. Okumura-Noji, and S. Yokoyama. 2001. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis. 159: 153-163.
53. Kakko, S., M. Tamminen, M. Paivansalo, H. Kauma, A. O. Rantala, M. Lilja, A. Reunanen, Y. A. Kesaniemi, and M. J. Savolainen. 2001. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur. J. Clin. Invest. 31: 593-602.
54. Meguro, S., I. Takei, M. Murata, H. Hirose, N. Takei, Y. Mitsuyoshi, K. Ishii, S. Oguchi, J. Shinohara, E. Takeshita, K. Watanabe, and T. Saruta. 2001. Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. Atherosclerosis. 156: 151-156.
55. Hannuksela, M., Y. L. Marcel, Y. A. Kesaniemi, and M. J. Savolainen. 1992. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J. Lipid Res. 33: 737-744.
56. Fumeron, F., D. Betoulle, G. Luc, I. Behague, S. Ricard, O. Poirier, R. Jemaa, A. Evans, D. Arveiler, and P. Marques-Vidal. 1995. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J. Clin. Invest. 96: 1664-1671.
57. Vohl, M. C., B. Lamarche, A. Pascot, G. Leroux, D. Prud'homme, C. Bouchard, A. Nadeau, and J. P. Despres. 1999. Contribution of the cholesteryl ester transfer protein gene TaqIB polymorphism to the reduced plasma HDL-cholesterol levels found in abdominal obese men with the features of the insulin resistance syndrome. Int. J. Obes. Relat. Metab. Disord. 23: 918-925.
58. Freeman, D. J., N. J. Samani, V. Wilson, A. D. McMahon, P. S. Braund, S. Cheng, M. J. Caslake, C. J. Packard, and D. Gaffney. 2003. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur. Heart J. 24: 1833-1842.
59. Blankenberg, S., H. J. Rupprecht, C. Bickel, X. C. Jiang, O. Poirier, K. J. Lackner, J. Meyer, F. Cambien, and L. Tiret. 2003. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J. Am. Coll. Cardiol. 41: 1983-1989.
60. de Grooth, G. J., K. E. Zerba, S. Huang, Z. Tsuchihashi, T. Kirchgessner, R. Belder, V. Vishnupad, B. Hu, A. H. E. M. Klerkx, A. H. Zwinderman, J. W. Jukema, F. Sacks, J. J. P. Kastelein, and J. A. Kuivenhoven. 2004. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol And Recurrent Events study (CARE): no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J. Am. Coll. Cardiol. 43: 854-857.
61. Barzilai, N., G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples, R. Lipton, S. Cheng, and A. R. Shuldiner. 2004. Unique lipoprotein phenotype and genotype associated with exceptional longevity. J. Am. Med. Assoc. 290: 2030-2040.
62. Bruce, C., D. S. Sharp, and A. R. Tall. 1998. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. 39: 1071-1078.
63. Le Goff, W., M. Guerin, and M. J. Chapman. 2004. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101: 17-38.
64. Bagdade, J. D., M. C. Ritter, and P. V. Subbaiah. 1991. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J. Clin. Invest. 87: 1259-1265.
65. McPherson, R., C. J. Mann, A. R. Tall, M. Hogue, L. Martin, R. W. Milne, and Y. L. Marcel. 1991. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 11: 797-804.
66. Sparks, D. L., J. Frohlich, A. G. Lacko, and P. H. Pritchard. 1989. Relationship between cholesteryl ester transfer activity and high density lipoprotein composition in hyperlipidemic patients. Atherosclerosis. 77: 183-191.
67. de Grooth, G. J., T. J. Smilde, S. van Wissen, A. H. E. M. Klerkx, A. H. Zwinderman, J. C. Fruchart, J. J. P. Kastelein, A. F. H. Stalenhoef, and J. A. Kuivenhoven. 2004. The relationship between cholesteryl ester transfer protein levels and risk factors in patients with familial hypercholesterolemia. Atherosclerosis. 173: 261-267.
68. Tall, A., E. Granot, R. Brocia, I. Tabas, C. Hesler, K., Williams, and M. Denke. 1987. Accelerated transfer of cholesteryl esters in dyslipidemic plasma: role of cholesteryl ester transfer protein. J. Clin. Invest. 79: 1217-1225.
69. Moulin, P., G. B. Appel, H. N. Ginsberg, and A. R. Tall. 1992. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J. Lipid Res. 33: 1817-1822.
70. van Tol, A. 1993. CETP-catalysed transfer of cholesterylesters from HDL to apo B-containing lipoproteins in plasma from diabetic patients (Letter). Eur. J. Clin. Invest. 23: 856.
71. Savolainen, M. J., M. Hannuksela, S. Seppanen, K. Kervinen, and Y. A. Kesaniemi. 1990. Increased high-density lipoprotein cholesterol concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur. J. Clin. Invest. 20: 593-599.
72. Seip, R. L., P. Moulin, T. Cocke, A. Tall, W. M. Kohrt, K. Mankowitz, C. F. Semenkovich, R. Ostlund, and G. Schonfeld. 1993. Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler. Thromb. 13: 1359-1367.
73. Dullaart, R. P., K. Hoogenberg, B. D. Dikkeschei, and A. van Tol. 1994. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler. Thromb. 14: 1581-1585.
74. Freeman, D. J., B. A. Griffin, E. Murray, G. M. Lindsay, D. Gaffney, C. J. Packard, and J. Shepherd. 1993. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur. J. Clin. Invest. 23: 630-640.
75. Foger, B., A. Ritsch, A. Doblinger, H. Wessels, and J. R. Patsch. 1996. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16: 1430-1436.
76. Tall, A. R. 1986. Plasma lipid transfer proteins. J. Lipid Res. 27: 361-367.
77. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-75.
78. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19: 1105-1110.
79. Hayek, T., L. Masucci-Magoulas, X. Jiang, A. Walsh, E. Rubin, J. L. Breslow, and A. R. Tall. 1995. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96: 2071-2074.
80. Foger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, H. B. Brewer, Jr., and S. Santamarina-Fojo. 1999. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274: 36912-36920.
81. Whitlock, M. E., T. L. Swenson, R. Ramakrishnan, M. T. Leonard, Y. L. Marcel, R. W. Milne, and A. R. Tall. 1989. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit: effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 84: 129-137.
82. Abbey, M., and G. D. Calvert. 1989. Effects of blocking plasma lipid transfer protein activity in the rabbit. Biochim. Biophys. Acta. 1003: 20-29.
83. Gaynor, B. J., T. Sand, R. W. Clark, R. J. Aiello, M. J. Bamberger, and J. B. Moberly. 1994. Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis. 110: 101-109.
84. Evans, G. F., W. R. Bensch, L. D. Apelgren, D. Bailey, R. F. Kauffman, T. F. Bumol, and S. H. Zuckerman. 1994. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J. Lipid Res. 35: 1634-1645.
85. Kothari, H. V., K. J. Poirier, W. H. Lee, and Y. Satoh. 1997. Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis. 128: 59-66.
86. Shinkai, H., K. Maeda, T. Yamasaki, H. Okamoto, and I. Uchida. 2000. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J. Med. Chem. 43: 3566-3572.
87. Rittershaus, C. W., D. P. Miller, L. J. Thomas, M. D. Picard, C. M. Honan, C. D. Emmett, C. L. Pettey, H. Adari, R. A. Hammond, D. T. Beattie, A. D. Callow, H. C. Marsh, and U. S. Ryan. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106-2112.
88. Huang, Z., A. Inazu, A. Nohara, T. Higashikata, and H. Mabuchi. 2002. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond.). 103: 587-594.
89. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273: 5033-5036.
90. Applebaum-Bowden, D., S. M. Haffner, E. Hartsook, K. H. Luk, J. J. Albers, and W. R. Hazzard. 1984. Down-regulation of the low-density lipoprotein receptor by dietary cholesterol. Am. J. Clin. Nutr. 39: 360-367.
91. Acton, S., D. Osgood, M. Donoghue, D. Corella, M. Pocovi, A. Cenarro, P. Mozas, J. Keilty, S. Squazzo, E. A. Woolf, and J. M. Ordovas. 1999. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler. Thromb. Vasc. Biol. 19: 1734-1743.
92. Osgood, D., D. Corella, S. Demissie, L. A. Cupples, P. W. Wilson, J. B. Meigs, E. J. Schaefer, O. Coltell, and J. M. Ordovas. 2003. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham Study. J. Clin. Endocrinol. Metab. 88: 2869-2879.
93. Acton, S., A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271: 518-520.
94. Rye, K. A., and P. J. Barter. 2004. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24: 421-428.
95. Shimoji, E., B. Zhang, P. Fan, and K. Saku. 2004. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis. 172: 247-257.
96. Carmena, R., P. Duriez, and J. C. Fruchart. 2004. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 109(SuppI.): III2-III7.
97. Sakai, N., Y. Matsuzawa, K. Hirano, S. Yamashita, S. Nozaki, Y. Ueyama, M. Kubo, and S. Tarui. 1991. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler. Thromb. 11: 71-79.